ImClone, Sanofi-Aventis Settle Erbitux Patent Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
Each company will pay Israel’s Yeda $60 million, but ImClone also gains license for a patent critical to the production of cetuximab.
You may also be interested in...
ImClone Tussles With Another Partner, Merck KGaA
Merck KGaA seeks more than $18 million in damages, alleging ImClone licensed rights to Erbitux patents it did not own.
ImClone Tussles With Another Partner, Merck KGaA
Merck KGaA seeks more than $18 million in damages, alleging ImClone licensed rights to Erbitux patents it did not own.
North American Erbitux Sales Up 17 Percent In First Quarter
Positive clinical trial data, increased promotional efforts with partner Bristol-Myers Squibb drive gains, ImClone reports.